Table 1. Clinical, histologic,... | American Society of Hematology

Table 1.

Clinical, histologic, immunophenotypic, and genotypic features of ALK⁺ DLBCL

Feature	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6
Age, y/sex	46/M	45/F	49/M	48/M	51/M	58/M
Clinical presentation	Supraclavicular and abdominal LN	Rapidly growing inguinal tumor	Systemic LN and epidural mass	Axillary LN	Systemic LN and splenomegaly	Supraclavicular LN and subarachnoid involvement
Stage	III	NA	IV	IA	IVA	IV
Treatment and outcome	Multiagent CT, relapsed after 5 mo, retreated with CT and RT, CR for 27 mo	NA	CHOP + RT PR, relapsed after 9 mo and has progressive disease	CT alone, CR following 27 mo	CT plus intrathecal MTX, relapsed, BMT, DOD 26 mo after diagnosis	CHOP + rituximab DOD 6 mo after diagnosis
Histology	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth with necrosis
ALK staining	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic
B-cell markers	CD20⁻, CD79a⁻, CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺
Ig staining	Not interpretable	λ⁺	IgAλ	IgAλ	IgAλ	Not interpretable
T-cell markers	CD4⁺, CD57⁺	CD4^−/+	CD4⁻, CD43⁻	CD4^−/+	CD4⁺, CD43⁻	CD4⁻
Others	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻	EMA⁺, CD30⁻	EMA⁺, CD30⁻ Bcl-2⁻
Karyotype	t(2;17;7)(p23;q23;q?22)	NA	NA	NA	NA	NA
FISH	CLTC-ALK	CLTC-ALK	CLTC-ALK	CLTC-ALK	NA	CLTC-ALK
RT-PCR	CLTC-ALK and full-length ALK	NA	NA	NA	CLTC-ALK and full-length ALK	NA

Feature	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6
Age, y/sex	46/M	45/F	49/M	48/M	51/M	58/M
Clinical presentation	Supraclavicular and abdominal LN	Rapidly growing inguinal tumor	Systemic LN and epidural mass	Axillary LN	Systemic LN and splenomegaly	Supraclavicular LN and subarachnoid involvement
Stage	III	NA	IV	IA	IVA	IV
Treatment and outcome	Multiagent CT, relapsed after 5 mo, retreated with CT and RT, CR for 27 mo	NA	CHOP + RT PR, relapsed after 9 mo and has progressive disease	CT alone, CR following 27 mo	CT plus intrathecal MTX, relapsed, BMT, DOD 26 mo after diagnosis	CHOP + rituximab DOD 6 mo after diagnosis
Histology	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth	Immunoblasts, plasmablasts, sinusoidal growth with necrosis
ALK staining	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic	Granular cytoplasmic
B-cell markers	CD20⁻, CD79a⁻, CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺	CD20⁻, CD79a⁻ CD138⁺
Ig staining	Not interpretable	λ⁺	IgAλ	IgAλ	IgAλ	Not interpretable
T-cell markers	CD4⁺, CD57⁺	CD4^−/+	CD4⁻, CD43⁻	CD4^−/+	CD4⁺, CD43⁻	CD4⁻
Others	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻, Bcl-2⁻	EMA⁺, CD30⁻	EMA⁺, CD30⁻	EMA⁺, CD30⁻ Bcl-2⁻
Karyotype	t(2;17;7)(p23;q23;q?22)	NA	NA	NA	NA	NA
FISH	CLTC-ALK	CLTC-ALK	CLTC-ALK	CLTC-ALK	NA	CLTC-ALK
RT-PCR	CLTC-ALK and full-length ALK	NA	NA	NA	CLTC-ALK and full-length ALK	NA

LN indicates lymph nodes; M, male; F, female; NA, not available; CT, chemotherapy; RT, radiotherapy; Ig, immunoglobulin; PR, partial remission; DOD, dead of disease; CR, complete remission; MTX, methotrexate; and BMT, bone marrow transplantation.

View Large

This Feature Is Available To Subscribers Only